Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems

MLA

Glasser, Stephen P., et al. “Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems.” Journal of Clinical Pharmacology, vol. 47, no. 9, Sept. 2007, p. 1074. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.193812849&authtype=sso&custid=ns315887.

APA

Glasser, S. P., Salas, M., & Delzell, E. (2007). Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Journal of Clinical Pharmacology, 47(9), 1074.

Chicago

Glasser, Stephen P., Maribel Salas, and Elizabeth Delzell. 2007. “Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems.” Journal of Clinical Pharmacology 47 (9): 1074. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.193812849&authtype=sso&custid=ns315887.